Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

(2021) Holger W. Auner et al.   AMERICAN JOURNAL OF HEMATOLOGY

Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age

(2020) Monika Engelhardt et al.   HAEMATOLOGICA

Estimation of Kidney Function in Oncology

(2019) Morgan A. Casal et al.   Clinical Journal of the American Society of Nephrology

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

(2018) Meletios Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

IMiDs for myeloma induced renal impairment

(2018) Maria Gavriatopoulou et al.   Oncotarget

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

(2011) M. Kropff et al.   HAEMATOLOGICA

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

(2010) Meletios Dimopoulos et al.   CANCER